Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft

被引:31
作者
Choi, Y
Kim, SY
Kim, SH
Yang, J
Park, K
Byun, Y
机构
[1] Kwangju Inst Sci & Technol, Dept Mat Sci & Engn, Gwangju 500712, South Korea
[2] Univ Ulsan, Coll Med, Dept Otolaryngol, Seoul, South Korea
[3] Sungkyunkwan Univ, Coll Med, Dept Clin Pathol, Seoul, South Korea
关键词
all-trans-retinoic acid; microsphere; head-and-neck cancer;
D O I
10.1002/ijc.11354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Retinoids play essential roles in the regulation of cell differentiation and in the proliferation of various epithelial tissues, and atRA is one such active metabolite of retinoids. However, despite the known functions of atRA, its clinical applications are limited due to the induced metabolism by the specific cytochrome P-450s in the liver. To overcome the limitation, parenteral administration of atRA-loaded biodegradable microspheres, the PDLLA/PLE microspheres containing atRA, was suggested previously. We evaluated chemotherapeutic efficacy of atRA-loaded microspheres in a human head-and-neck xenograft/nude mouse model. When atRA-loaded microspheres were administered s.c. at 200 mg/kg body weight to athymic nude mice, plasma concentration of atRA could be maintained in a range of 1.2 to 3.7 X 10(-8) M for 4 weeks. As a result, the tumor volume of human head-and-neck cancer was reduced compared to the control group by 51.3% (p < 0.01) at 14 days and by 49.2% (p < 0.05) at 28 days. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:145 / 148
页数:4
相关论文
共 30 条
[1]  
ACHKAR CC, 1994, DRUG METAB DISPOS, V22, P451
[2]   DETERMINATION OF ISOTRETINOIN OR ETRETINATE AND THEIR MAJOR METABOLITES IN HUMAN-BLOOD BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BUGGE, CJL ;
RODRIGUEZ, LC ;
VANE, FM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1985, 3 (03) :269-277
[3]   In vivo biocompatibility studies of poly(D,L-lactide)/poly(ethylene glycol)-poly(L-lactide) microspheres containing all-trans-retinoic acid [J].
Choi, Y ;
Kim, SY ;
Kim, SH ;
Park, TG ;
Moon, HT ;
Byun, Y .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2002, 13 (03) :301-322
[4]   Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres [J].
Choi, Y ;
Kim, SY ;
Kim, SH ;
Lee, KS ;
Kim, C ;
Byun, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 215 (1-2) :67-81
[5]  
CULLUM ME, 1985, J BIOL CHEM, V260, P590
[6]   Gliadin nanoparticles for the controlled release of all-trans-retinoic acid [J].
Ezpeleta, I ;
Irache, JM ;
Stainmesse, S ;
Chabenat, C ;
Gueguen, J ;
Popineau, Y ;
Orecchioni, AM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 131 (02) :191-200
[7]   THE RETINOIC ACID SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA [J].
FRANKEL, SR ;
EARDLEY, A ;
LAUWERS, G ;
WEISS, M ;
WARRELL, RP .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (04) :292-296
[8]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[9]   TRETINOIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND USE IN THE MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].
GILLIS, JC ;
GOA, KL .
DRUGS, 1995, 50 (05) :897-923
[10]  
Hong WK, 1995, CLIN CANCER RES, V1, P677